Supplementary Tables S1-S2, Figures S1-S8 from Targeting OCT2 with Duloxetine to Prevent Oxaliplatin-induced Peripheral Neurotoxicity

Supplementary Table S1. Percentage of OCT2 inhibition by compounds reported to reduce platinum-induced toxicities. Supplementary Table S2. Validation of human, rat, and murine overexpressed cells by evaluating their ability to accumulate known prototypical transport substrates. Supplementary Figure S1. Chemical structure of duloxetine. Supplementary Figure S2. IVIS imaging of tumor bearing mice. Supplementary Figure S3. Metabolites of duloxetine do not inhibit OCT2 function. Supplementary Figure S4. Duloxetine is an OCT2 inhibitor that extensively binds to extracellular membrane. Supplementary Figure S5. Duloxetine does not prevent peripheral neurotoxicity associated with vincristine and paclitaxel. Supplementary Figure S6. Paw withdrawal force measured by VFH instrument before the start of the treatment in wild-type (WT) and OCT1/2(-/-) mice (n=5-10 per group). Supplementary Figure S7. Activity of oxaliplatin in various colorectal cancer cell lines. Supplementary Figure S8. Effect of duloxetine on sciatic and caudal nerve velocity and amplitude.